文献速递慢性肾脏病肾移植

镰状细胞病相关肾衰竭患者的死亡与肾移植可及性

Mortality and Access to Kidney Transplantation in Patients with Sickle Cell Disease-Associated Kidney Failure.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-02-25

基于美国国家登记数据,1998-2017年成人肾衰竭患者中,镰状细胞病组移植受者10年死亡绝对风险差为20.3个百分点,与对照组19.8个百分点相近,死亡风险比分别为0.57和0.54;但镰状细胞病组接受移植的可能性显著低于对照组(亚分布风险比0.73),等候名单上亦存在差异(0.62)。

要点

  • 镰状细胞病相关肾衰竭患者移植后死亡风险降低程度与其他病因肾衰竭患者相似。
  • 镰状细胞病组接受肾移植的可能性显著低于对照组,等候名单上同样存在差异。
  • 移植对镰状细胞病相关肾衰竭患者的生存获益与其他病因相似,但移植可及性受限。

核心结论

  • 镰状细胞病相关肾衰竭患者接受肾移植与死亡风险降低相关,程度与其他病因肾衰竭患者相似。
  • 镰状细胞病人群接受移植的可能性更低,即使在等待名单注册后仍存在差异。

研究设计与样本

  • 基于美国国家登记数据的回顾性队列研究,纳入1998-2017年开始维持性透析或加入肾移植等待名单的所有成人肾衰竭患者。
  • 采用匹配对分析比较移植受者与等待名单候选者的死亡风险,并以死亡为竞争风险估计接受移植的风险比。

主要发现

  • 镰状细胞病组189例移植受者与匹配等待候选者相比,10年死亡绝对风险差为20.3个百分点(98.75% CI 0.9至39.8)。
  • 对照组220251例移植受者10年死亡绝对风险差为19.8个百分点(98.75% CI 19.2至20.4)。
  • 镰状细胞病组死亡风险比为0.57(95% CI 0.36至0.91),对照组为0.54(95% CI 0.53至0.55),交互作用P=0.8。
  • 镰状细胞病组接受移植的亚分布风险比为0.73(95% CI 0.61至0.87),低于对照组。
  • 在等待名单候选者中,镰状细胞病组接受移植的亚分布风险比为0.62(95% CI 0.53至0.72)。

临床怎么用

  • 对于镰状细胞病相关肾衰竭患者,肾移植可显著降低死亡风险,应积极评估移植适宜性。
  • 需关注该人群移植可及性较低的问题,尤其在等待名单注册后仍存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Patients with sickle cell disease-associated kidney failure have high mortality, which might be lowered by kidney transplantation. However, because they show higher post-transplant mortality compared with patients with other kidney failure etiologies, kidney transplantation remains controversial in this population, potentially limiting their chance of receiving transplantation. We aimed to quantify the decrease in mortality associated with transplantation in this population and determine the chance of receiving transplantation with sickle cell disease as the cause of kidney failure as compared with other etiologies of kidney failure. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using a national registry, we studied all adults with kidney failure who began maintenance dialysis or were added to the kidney transplant waiting list in 1998-2017. To quantify the decrease in mortality associated with transplantation, we measured the absolute risk difference and hazard ratio for mortality in matched pairs of transplant recipients versus waitlisted candidates in the sickle cell and control groups. To compare the chance of receiving transplantation, we estimated hazard ratios for receiving transplantation in the sickle cell and control groups, treating death as a competing risk. RESULTS: Compared with their matched waitlisted candidates, 189 transplant recipients with sickle cell disease and 220,251 control recipients showed significantly lower mortality. The absolute risk difference at 10 years post-transplant was 20.3 (98.75% confidence interval, 0.9 to 39.8) and 19.8 (98.75% confidence interval, 19.2 to 20.4) percentage points in the sickle cell and control groups, respectively. The hazard ratio was also similar in the sickle cell (0.57; 95% confidence interval, 0.36 to 0.91) and control (0.54; 95% confidence interval, 0.53 to 0.55) groups (interaction P=0.8). Nonetheless, the sickle cell group was less likely to receive transplantation than the controls (subdistribution hazard ratio, 0.73; 95% confidence interval, 0.61 to 0.87). Similar disparities were found among waitlisted candidates (subdistribution hazard ratio, 0.62; 95% confidence interval, 0.53 to 0.72). CONCLUSIONS: Patients with sickle cell disease-associated kidney failure exhibited similar decreases in mortality associated with kidney transplantation as compared with those with other kidney failure etiologies. Nonetheless, the sickle cell population was less likely to receive transplantation, even after waitlist registration.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Bae S, Johnson M, Massie AB, et al. Mortality and Access to Kidney Transplantation in Patients with Sickle Cell Disease-Associated Kidney Failure. Clin J Am Soc Nephrol. 2021. PMID: 33632759. doi:10.2215/CJN.02720320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。